Primary Cardiac Lymphoma in an Immunocompetent 71-Year-Old Man

Tex Heart Inst J. 2015 Dec 1;42(6):561-4. doi: 10.14503/THIJ-14-4269. eCollection 2015 Dec.

Abstract

Isolated cardiac lymphomas are very rare, especially in immunocompetent patients. As a consequence, little is known about the best therapeutic management and about patients' outcomes in these cases. Diffuse large B-cell lymphoma is the most frequent subtype; anthracycline-based chemotherapy has been the most successful treatment. We describe the case of a primary cardiac lymphoma in an immunocompetent 71-year-old man. As of December 2015, the patient had been in clinical remission for 2 years. The most relevant literature on primary cardiac lymphoma is reported and discussed.

Keywords: Biopsy, endomyocardial; cyclophosphamide; etoposide; heart neoplasms/therapy; immunocompetence; lymphoma, large B-cell, diffuse/diagnosis/drug therapy; lymphoma, non-Hodgkin/drug therapy; prednisone; rituximab; vincristine.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Heart Neoplasms* / drug therapy
  • Heart Neoplasms* / immunology
  • Heart Neoplasms* / pathology
  • Humans
  • Immunocompetence*
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / immunology
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Male
  • Prednisone / therapeutic use
  • Remission Induction
  • Rituximab
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone